Preclinical efficacy and immunogenicity assessment to show that a chimeric Plasmodium falciparum UB05‐09 antigen could be a malaria vaccine candidate

Although it is generally agreed that an effective vaccine would greatly accelerate the control of malaria, the lone registered malaria vaccine Mosquirix™ has an efficacy of 30%‐60% that wanes rapidly, indicating a need for improved second‐generation malaria vaccines. Previous studies suggested that...

Descripción completa

Detalles Bibliográficos
Autores principales: Dinga, J. N., Gamua, S. D., Ghogomu, S. M., Titanji, V. P. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873454/
https://www.ncbi.nlm.nih.gov/pubmed/29284177
http://dx.doi.org/10.1111/pim.12514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873454/
https://www.ncbi.nlm.nih.gov/pubmed/29284177
http://dx.doi.org/10.1111/pim.12514

Ejemplares similares